US FDA extends review of Rhythm Pharma's drug for rare form of obesity
07/11/2025 12:37
Nov 7 (Reuters) - Rhythm Pharmaceuticals RYTM.O said on Friday the U.S. Food and Drug Administration has extended the review period for expanded approval of its drug, Imcivree, as a treatment for a rare form of obesity. (Reporting by Sneha S K; Editing by Sahal Muhammed) ((Sneha.SK@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand